Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Gains from Investment Securities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Gains from Investment Securities for 8 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 34.88% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.0 million through Dec 2025, up 902.11% year-over-year, with the annual reading at $125500.0 for FY2025, 2841.18% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $2.8 million at Outlook Therapeutics, down from $40.4 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $40.4 million in Q3 2025, with the low at $304636.0 in Q2 2025.